We are changing the way medicine is delivered...
...one Micro-Needle at a time!
Changing the way medicine is administered
TO LEARN MORE OR
FOR INVESTMENT OPPORTUNITIES...
The PKA SoftTouch Vision
To be recognized by medical/pharmaceutical professionals, physicians and patients as the most cost effective, pain-free, safe, single-shot and disposable intradermal device available in the injectable drug market.
This painless device will improve the quality of life, and increase the patients' acceptance of taking their daily required medications. The single shot device will make it easy to inoculate populations overseas that suffer from chronic diseases. This single shot device can be disposed of in ordinary waste after use.
The PKA SoftTouch Business Model
PKA follows a licensing model for revenue generation. In order to access drugs required for filling the Micro-Needle, a contract with a drug manufacturer is required. PKA will license its technology to the pharmaceutical manufacturer in order to obtain access to the drug for the device. The drug company will fill the Micro-Needle with their drug and utilize their sales, marketing, and distribution channels to bring the pre-filled device to market. A licensing agreement will generate revenue through front-end payments, and milestone payments, followed by more important on-going royalties, thus creating a constant revenue stream. Licensing the technology to other different drug companies ensures ongoing long term revenue growth for the corporation.
PKA's Business Plan
PKA SoftTouch Corp. was founded to bring its unique and revolutionary device to the growing worldwide injectable drug marketplace.
The injectable drug market is set to grow at a
14% compounded annual growth rate and to reach $43.3 billion in 2017
Since the company's inception, many of our activities have centered on design and development of device prototypes, testing of the prototypes, development of the filling process and equipment and obtaining patent protection. We have developed strategic partnerships with local research and development partners and sourcing materials compliant with pharmaceutical regulatory standards.
PKA is now entering the final Research & Development phase; completion of this phase will lead to commercialization and revenue generation. An additional $2 million in funding will be required to support these activities. A number of funding strategies have been identified and implementation has begun.
Key strategic objectives for the next 24 months:
SAFE, SIMPLE & PAIN FREE
THE PKA MICRO-NEEDLE REPLACES THE SYRINGE WITH A PAINLESS INTERDERMAL DELIVERY SYSTEM